α-naphthoflavone treatment reduced oxidative stress and insulin resistance as well as mitigated NAFLD by modulation of AhR regulated Cyp1a1 and TNFα pathways [90]. Here, AHR is linked to metabolic dysfunction-associated steatotic liver disease.